Bio-Path Shares Trading At Daily High Up 186% After Co Reported Phase 2 Trial Of Bp1001 For The Treatment Of Acute Myeloid Leukemia Demonstrated 'Meaningful Clinical Improvement' With An 'Excellent' Patient Safety Profile